作为治疗炎症性疾病的MRGPRX2拮抗剂的新型双环杂环化合物
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2025 Apr 2;16(5):732-733. doi: 10.1021/acsmedchemlett.5c00165. eCollection 2025 May 8.
Abstract
Provided herein are novel bicyclic heterocycles as MRGPRX2 antagonists, pharmaceutical compositions, use of such compounds in treating inflammatory diseases, and processes for preparing such compounds.
摘要
本文提供了作为MRGPRX2拮抗剂的新型双环杂环化合物、药物组合物、此类化合物在治疗炎症性疾病中的用途以及制备此类化合物的方法。
相似文献
1
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.
ACS Med Chem Lett. 2025 Apr 2;16(5):732-733. doi: 10.1021/acsmedchemlett.5c00165. eCollection 2025 May 8.
2
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.
ACS Med Chem Lett. 2025 Jun 2;16(6):980-981. doi: 10.1021/acsmedchemlett.5c00305. eCollection 2025 Jun 12.
3
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
4
Bicyclic Ureas as JAK2 Inhibitors for Treating Hematological Cancer.
ACS Med Chem Lett. 2024 Oct 29;15(11):1824-1825. doi: 10.1021/acsmedchemlett.4c00496. eCollection 2024 Nov 14.
5
Novel Bicyclic Amines as CDK2 Inhibitors for Treating Metastatic Breast Cancer or Metastatic Lung Cancer.
ACS Med Chem Lett. 2025 Jan 16;16(2):198-199. doi: 10.1021/acsmedchemlett.5c00005. eCollection 2025 Feb 13.
6
Novel Bicyclic DGK Inhibitors for Treating Metastatic Melanoma.
ACS Med Chem Lett. 2025 Apr 2;16(5):728-729. doi: 10.1021/acsmedchemlett.5c00164. eCollection 2025 May 8.
7
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.
ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13.
8
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
9
Novel Imidazotriazine Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Disorders.
ACS Med Chem Lett. 2024 Dec 10;16(1):12-13. doi: 10.1021/acsmedchemlett.4c00573. eCollection 2025 Jan 9.
10
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
引用本文的文献
1
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.
ACS Med Chem Lett. 2025 Jun 2;16(6):980-981. doi: 10.1021/acsmedchemlett.5c00305. eCollection 2025 Jun 12.
本文引用的文献
1
Mast Cells and Mas-related G Protein-coupled Receptor X2: Itching for Novel Pathophysiological Insights to Clinical Relevance.
Curr Allergy Asthma Rep. 2024 Nov 25;25(1):5. doi: 10.1007/s11882-024-01183-5.
2
Mast cell modulation: A novel therapeutic strategy for abdominal pain in irritable bowel syndrome.
Cell Rep Med. 2024 Oct 15;5(10):101780. doi: 10.1016/j.xcrm.2024.101780. Epub 2024 Oct 7.
3
The evolving role of mast cells in wound healing: insights from recent research and diverse models.
Immunol Cell Biol. 2024 Nov;102(10):878-890. doi: 10.1111/imcb.12824. Epub 2024 Oct 8.
4
The MRGPR family of receptors in immunity.
Immunity. 2024 Jan 9;57(1):28-39. doi: 10.1016/j.immuni.2023.12.012.
Zotero 插件